The Epidermal Barrier in Atopic Dermatitis

Seminars in Cutaneous Medicine and Surgery

Volumn 27, Issue 2, 2008, Pages 108-114

  Sugarman, Jeffrey L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ATOPICLAIR; CALCINEURIN INHIBITOR; CERAMIDE DERIVATIVE; CERATOPIC; CERAVE; CLOBETASOL PROPIONATE; CORTICOSTEROID; DERMATOLOGICAL AGENT; EMOLLIENT AGENT; EMULSIFYING AGENT; EPICERAM; FILAGGRIN; FLUTICASONE; FLUTICASONE PROPIONATE; HUMECTANT; MIMYX; NON PRESCRIPTION DRUG; PETROLATUM; PHYSIOGEL; SPHINGOSINE; STEROID; TRICERAM;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATOPIC DERMATITIS; CLINICAL FEATURE; CLINICAL TRIAL; DERMOEPIDERMAL JUNCTION; DISEASE ASSOCIATION; DISEASE SEVERITY; DNA POLYMORPHISM; EPIDERMIS; GENE MUTATION; GENETIC PREDISPOSITION; HUMAN; HYDROGEL; HYGIENE; IMMUNE DEFICIENCY; MONOTHERAPY; NETHERTON DISEASE; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN ALLERGY; SKIN CARE; SKIN FUNCTION; SKIN INFLAMMATION; SKIN INJURY; SKIN PERMEABILITY; SKIN PROTECTION; TREATMENT INDICATION; WOUND DRESSING;

DERMATITIS, ATOPIC; HUMANS; RISK FACTORS; SKIN; SKIN ABSORPTION;

EID: 46649094397     PISSN: 10855629     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sder.2008.04.005     Document Type: Article

References (64)

1. Leung D.Y. Atopic dermatitis: New insights and opportunities for therapeutic intervention. J Allergy Clin Immunol 105 (2000) 860-876
2. Elias P.M., Wood L.C., and Feingold K.R. Epidermal pathogenesis of inflammatory dermatoses. Am J Contact Dermat 10 (1999) 119-126
3. Elias P.M. Epidermal lipids, barrier function, and desquamation. J Invest Dermatol suppl 44s-49s (1983) 80
4. Elias P.M., and Feingold K.R. Does the tail wag the dog?. Role of the barrier in the pathogenesis of inflammatory dermatoses and therapeutic implications. Arch Dermatol 137 (2001) 1079-1081
5. Descargues P., Deraison C., Bonnart C., et al. Spink5-deficient mice mimic Netherton syndrome through degradation of desmoglein 1 by epidermal protease hyperactivity. Nat Genet 37 (2005) 56-65
6. Nickoloff B.J., and Naidu Y. Perturbation of epidermal barrier function correlates with initiation of cytokine cascade in human skin. J Am Acad Dermatol 30 (1994) 535-546
7. Seidenari S., and Giusti G. Objective assessment of the skin of children affected by atopic dermatitis: A study of pH, capacitance and TEWL in eczematous and clinically uninvolved skin. Acta Derm Venereol 75 (1995) 429-433
8. Proksch E., Folster-Holst R., and Jensen J.M. Skin barrier function, epidermal proliferation and differentiation in eczema. J Dermatol Sci 43 (2006) 159-169
9. Chamlin S.L., Kao J., Frieden I.J., et al. Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: Changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol 47 (2002) 198-208
10. Sugarman J.L., Fluhr J.W., Fowler A.J., et al. The objective severity assessment of atopic dermatitis score: An objective measure using permeability barrier function and stratum corneum hydration with computer-assisted estimates for extent of disease. Arch Dermatol 139 (2003) 1417-1422
11. Palmer C.N., Irvine A.D., Terron-Kwiatkowski A., et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 38 (2006) 441-446
12. Sandilands A., O'Regan G.M., Liao H., et al. Prevalent and rare mutations in the gene encoding filaggrin cause ichthyosis vulgaris and predispose individuals to atopic dermatitis. J Invest Dermatol 126 (2006) 1770-1775
13. Weidinger S., Illig T., Baurecht H., et al. Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations. J Allergy Clin Immunol 118 (2006) 214-219
14. Walley A.J., Chavanas S., Moffatt M.F., et al. Gene polymorphism in Netherton and common atopic disease. Nat Genet 29 (2001) 175-178
15. Fartasch M. Epidermal barrier in disorders of the skin. Microsc Res Tech 38 (1997) 361-372
16. Di Nardo A., Wertz P., Giannetti A., et al. Ceramide and cholesterol composition of the skin of patients with atopic dermatitis. Acta Derm Venereol 78 (1998) 27-30
17. Macheleidt O., Kaiser H.W., and Sandhoff K. Deficiency of epidermal protein-bound omega-hydroxyceramides in atopic dermatitis. J Invest Dermatol 119 (2002) 166-173
18. Di Nardo A., Wertz P., Giannetti A., et al. Ceramide and cholesterol composition of the skin of patients with atopic dermatitis. Acta Derm Venereol 78 (1998) 27-30
19. Hara J., Higuchi K., Okamoto R., et al. High-expression of sphingomyelin deacylase is an important determinant of ceramide deficiency leading to barrier disruption in atopic dermatitis. J Invest Dermatol 115 (2000) 406-413
20. Aly R., Maibach H.I., and Shinefield H.R. Microbial flora of atopic dermatitis. Arch Dermatol 113 (1977) 780-782
21. Baker B.S. The role of microorganisms in atopic dermatitis. Clin Exp Immunol 144 (2006) 1-9
22. Arikawa J., Ishibashi M., Kawashima M., et al. Decreased levels of sphingosine, a natural antimicrobial agent, may be associated with vulnerability of the stratum corneum from patients with atopic dermatitis to colonization by Staphylococcus aureus. J Invest Dermatol 119 (2002) 433-439
23. Ohnishi Y., Okino N., Ito M., et al. Ceramidase activity in bacterial skin flora as a possible cause of ceramide deficiency in atopic dermatitis. Clin Diagn Lab Immunol 6 (1999) 101-104
24. Braff M.H., Di Nardo A., and Gallo R.L. Keratinocytes store the antimicrobial peptide cathelicidin in lamellar bodies. J Invest Dermatol 124 (2005) 394-400
25. McGirt L.Y., and Beck L.A. Innate immune defects in atopic dermatitis. J Allergy Clin Immunol 118 (2006) 202-208
26. Rieg S., Steffen H., Seeber S., et al. Deficiency of dermcidin-derived antimicrobial peptides in sweat of patients with atopic dermatitis correlates with an impaired innate defense of human skin in vivo. J Immunol 174 (2005) 8003-8010
27. Bieber T. Atopic dermatitis. N Engl J Med 358 (2008) 1483-1494
28. Hannifin J. Eczema (1992), Dunitz, London
29. Barker D.E. Skin thickness in the human. Plast Reconstr Surg 7 (1951) 115-116
30. Lee Y., and Hwang K. Skin thickness of Korean adults. Surg Radiol Anat 24 (2002) 183-189
31. Paller A., and Mancini A. Hurwitz Clinical Pediatric Dermatology. (ed 3) (2006), Sanders, Phildelphia, Elsevier
32. Lee H.J., Ha S.J., Ahn W.K., et al. Clinical evaluation of atopic hand-foot dermatitis. Pediatr Dermatol 18 (2001) 102-106
33. Gerhardt L.C., Strassle V., Lenz A., et al. Influence of epidermal hydration on the friction of human skin against textiles. J R Soc Interface (2008)
34. Knapik J.J., Reynolds K.L., Duplantis K.L., et al. Friction blisters. Pathophysiology, prevention and treatment. Sports Med 20 (1995) 136-147
35. Kim M.K., Patel R.A., Shinn A.H., et al. Evaluation of gender difference in skin type and pH. J Dermatol Sci 41 (2006) 153-156
36. Schmid-Wendtner M.H., and Korting H.C. The pH of the skin surface and its impact on the barrier function. Skin Pharmacol Physiol 19 (2006) 296-302
37. Voegeli D. The effect of washing and drying practices on skin barrier function. J Wound Ostomy Continence Nurs 35 (2008) 84-90
38. Baranda L., Gonzalez-Amaro R., Torres-Alvarez B., et al. Correlation between pH and irritant effect of cleansers marketed for dry skin. Int J Dermatol 41 (2002) 494-499
39. Solodkin G., Chaudhari U., Subramanyan K., et al. Benefits of mild cleansing: Synthetic surfactant based (syndet) bars for patients with atopic dermatitis. Cutis 77 (2006) 317-324
40. Garg A., Chren M.M., Sands L.P., et al. Psychological stress perturbs epidermal permeability barrier homeostasis: Implications for the pathogenesis of stress-associated skin disorders. Arch Dermatol 137 (2001) 53-59
41. Denda M., Tsuchiya T., Elias P.M., et al. Stress alters cutaneous permeability barrier homeostasis. Am J Physiol Regul Integr Comp Physiol 278 (2000) R367-R372
42. Aberg K.M., Radek K.A., Choi E.H., et al. Psychological stress downregulates epidermal antimicrobial peptide expression and increases severity of cutaneous infections in mice. J Clin Invest 117 (2007) 3339-3349
43. Cork M.J., Robinson D.A., Vasilopoulos Y., et al. New perspectives on epidermal barrier dysfunction in atopic dermatitis: gene-environment interactions. J Allergy Clin Immunol 118 (2006) 3-21 quiz 22-23
44. Kolbe L., Kligman A.M., Schreiner V., et al. Corticosteroid-induced atrophy and barrier impairment measured by non-invasive methods in human skin. Skin Res Technol 7 (2001) 73-77
45. Kao J.S., Fluhr J.W., Man M.Q., et al. Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: Inhibition of epidermal lipid synthesis accounts for functional abnormalities. J Invest Dermatol 120 (2003) 456-464
46. Sheu H.M., Lee J.Y., Chai C.Y., et al. Depletion of stratum corneum intercellular lipid lamellae and barrier function abnormalities after long-term topical corticosteroids. Br J Dermatol 136 (1997) 884-890
47. Zheng P.S., Lavker R.M., Lehmann P., et al. Morphologic investigations on the rebound phenomenon after corticosteroid-induced atrophy in human skin. J Invest Dermatol 82 (1984) 345-352
48. Berth-Jones J., Damstra R.J., Golsch S., et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: Randomised, double blind, parallel group study. BMJ 326 (2003) 1367
49. Glazenburg EJ, Wolkerstorfer A, Gerretsen AL, et al: Efficacy and safety of fluticasone propionate 0.005% ointment in the long-term maintenance treatment of children with atopic dermatitis: Differences between boys and girls? Pediatr Allergy Immunol, in press
50. Szczepanowska J, Reich A, Szepietowski JC: Emollients improve treatment results with topical corticosteroids in childhood atopic dermatitis: A randomized comparative study. Pediatr Allergy Immunol, in press
51. Cork M.J., Britton J., Butler L., et al. Comparison of parent knowledge, therapy utilization and severity of atopic eczema before and after explanation and demonstration of topical therapies by a specialist dermatology nurse. Br J Dermatol 149 (2003) 582-589
52. Williams M.L., and Elias P.M. Elevated n-alkanes in congenital ichthyosiform erythroderma. Phenotypic differentiation of two types of autosomal recessive ichthyosis. J Clin Invest 74 (1984) 296-300
53. Ghadially R., Halkier-Sorensen L., and Elias P.M. Effects of petrolatum on stratum corneum structure and function. J Am Acad Dermatol 26 (1992) 387-396
54. Man M.M., Feingold K.R., Thornfeldt C.R., et al. Optimization of physiological lipid mixtures for barrier repair. J Invest Dermatol 106 (1996) 1096-1101
55. Mao-Qiang M., Brown B.E., Wu-Pong S., et al. Exogenous nonphysiologic vs physiologic lipids. Divergent mechanisms for correction of permeability barrier dysfunction. Arch Dermatol 131 (1995) 809-816
56. Proksch E., Jensen J.M., and Elias P.M. Skin lipids and epidermal differentiation in atopic dermatitis. Clin Dermatol 21 (2003) 134-144
57. Chamlin S.L., Frieden I.J., Fowler A., et al. Ceramide-dominant, barrier-repair lipids improve childhood atopic dermatitis. Arch Dermatol 137 (2001) 1110-1112
58. Vavrova K., Hrabalek A., Mac-Mary S., et al. Ceramide analogue 14S24 selectively recovers perturbed human skin barrier. Br J Dermatol 157 (2007) 704-712
59. Breternitz M., Kowatzki D., Langenauer M., et al. Placebo-controlled, double-blind, randomized, prospective study of a glycerol-based emollient on eczematous skin in atopic dermatitis: biophysical and clinical evaluation. Skin Pharmacol Physiol 21 (2008) 39-45
60. Eberlein B., Eicke C., Reinhardt H.W., et al. Adjuvant treatment of atopic eczema: Assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). J Eur Acad Dermatol Venereol 22 (2008) 73-82
61. Belloni G., Pinelli S., and Veraldi S. A randomised, double-blind, vehicle-controlled study to evaluate the efficacy and safety of MAS063D (Atopiclair) in the treatment of mild to moderate atopic dermatitis. Eur J Dermatol 15 (2005) 31-36
62. Abramovits W., and Boguniewicz M. A multicenter, randomized, vehicle-controlled clinical study to examine the efficacy and safety of MAS063DP (Atopiclair) in the management of mild to moderate atopic dermatitis in adults. J Drugs Dermatol 5 (2006) 236-244
63. Patrizi A., Capitanio B., Neri I., et al. A double-blind, randomized, vehicle-controlled clinical study to evaluate the efficacy and safety of MAS063DP (ATOPICLAIR(TM)) in the management of atopic dermatitis in paediatric patients. Pediatr Allergy Immunol (2008)
64. Sugarman J.L., and Parish L. A topical physiologic lipid-based, barrier repair formulation (EpiCeram® cream) is highly effective monotherapy for moderate to severe pediatric atopic dermatitis. J Invest Dermatol 128 (2008) S54